statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Bausch Health misses Q1 EPS estimates at 59 cents, despite a revenue increase of 11%.
read more...

Why Bausch Health Companies Shares Are Falling After Q1 Results

LAVAL, QC / ACCESSWIRE / April 5, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) along with its gastroenterology business, Salix Pharmaceuticals, Inc., announced that it filed a lawsuit...

Bausch Health Announces Patent Lawsuit Against Amneal Pharmaceuticals

Bausch Health Companies Inc. (NYSE:BHC - Free Report) - Analysts at Zacks Research lifted their FY2026 earnings per share estimates for Bausch Health Companies in a research report issued to clients...

Zacks Research Comments on Bausch Health Companies Inc.'s FY2026 Earnings (NYSE:BHC)

Salix Pharmaceuticals Releases Fourth Annual Patient Perspectives IBS Impact ReportLAVAL, QC / ACCESSWIRE / April 2, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology...

Based on a New Survey, More Than Half of Surveyed IBS/CIC Patients Feel Alone in Their Experience but Also Find That Social Media Helps Create a Community and Inspires Healthcare Provider Conversations

Key Insights Significantly high institutional ownership implies Bausch Health Companies' stock price is sensitive to...

Institutional investors control 64% of Bausch Health Companies Inc. (NYSE:BHC) and were rewarded last week after stock increased 12%

Check out Chou RRSP Fund Stock Picks '

 Download GuruFolio Report of Chou RRSP Fund (Updated on 03/31/2024)Related Stocks: TSX:TWC, EXCE, TSX:BHC, TSXV:RET, TSX:LNR, TSX:HCG...

Chou RRSP Fund Exits Home Capital Group with Notable Portfolio Impact

Citigroup Inc. boosted its stake in shares of Bausch Health Companies Inc. (NYSE:BHC - Free Report) by 73.3% during the third quarter, according to the company in its most recent filing with the...

Citigroup Inc. Buys 8,804 Shares of Bausch Health Companies Inc. (NYSE:BHC)

In this article, we discuss the losses incurred by Carl Icahns 10 activist targets over the long term. You can skip our detailed analysis of Icahns activist targets and their historical...

The Enduring Losses Incurred by Carl Icahn's 10 Activist Targets over the Long Term

This is a signal that BHC's price could be shifting from an uptrend to a downtrend. Traders may consider selling the stock or exploring put options...

Bausch Health Companies (BHC, $10.49) RSI Indicator left the overbought zone on March 27, 2024

Investors in Bausch Health Companies Inc (BHC) saw new options begin trading today, for the May 10th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the BHC...

May 10th Options Now Available For Bausch Health Companies (BHC)

Bausch Health Cos., Inc. engages in the development, manufacture and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: Salix, International, Solta Medical, Diversified Products, and Bausch + Lomb. The Salix segment consists of sales in the U.S. of GI products. Sales of the Xifaxan product line. The International segment comprises of sales, except for sales of Bausch + Lomb products and Solta aesthetic medical devices, outside the U.S and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical and OTC products. The Solta Medical segment refers to global sales of Solta Medical aesthetic medical devices. The Diversified Products segment covers sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, generic products, ortho dermatologic, and dentistry products. The Bausch + Lomb segment are global sales of Bausch + Lomb vision care, surgical and ophthalmic pharmaceuticals products. The company was founded on March 29, 1994, and is headquartered in Laval, Canada.

Volume	3.39M
52-Wk High	$11.46
52-Wk Low	$5.57

Period	Estimated	Reported	Surprise	Result
Q2'24	$0.88	--	--	N/A
Q1'24	$0.68	$0.63	-7.38%	MISSED
Q4'23	$1.02	$0.97	-4.78%	MISSED
Q3'23	$0.92	$1.07	17.19%	BEAT
Q2'23	$0.71	$0.82	14.92%	BEAT

BHC Bausch Health Companies Inc

About

Feed

News

Sentiment

Earnings

Fundamentals